论文部分内容阅读
目的探析CYFRA21-1、NSE以及CEA等肿瘤标志物检验运用在肺癌患者中的临床效果。方法选择2014年1月~2015年1月期间我院收治的肺部良性病变患者101例和肺癌患者95例为研究对象,再选择70例同期健康体检者作为对照组,分别对其进行CEA、NSE以及CYFRA21-1肿瘤标志物检验,对比分析三组的检测结果。结果相比较对照组和肺良性病变组而言,肺癌组患者的CYFRA21-1、NSE以及CEA水平均较高,组间对比差异明显(P<0.05);肺癌组中CYFRA21-1、NSE以及CEA的阳性率分别为68.42%(65/95)、36.84%(35/95)、73.68%(70/95),并且联合检测阳性率为95.79%(91/95);同时,肺癌组中不同病理分型的CYFRA21-1、N S E以及C E A水平对比有统计学意义(P<0.05)。结论临床上给予肺癌患者CYFRA21-1、NSE以及CEA等肿瘤标志物检验,不仅可以提高诊断准确率,还有助于判断预后。
Objective To explore the clinical effects of CYFRA21-1, NSE, CEA and other tumor markers used in lung cancer patients. Methods From January 2014 to January 2015, 101 patients with benign pulmonary lesions and 95 patients with lung cancer were selected as study subjects, and 70 patients with healthy physical examination were selected as the control group. NSE and CYFRA21-1 tumor markers were examined and the results of the three groups were analyzed and compared. Results The levels of CYFRA21-1, NSE, and CEA in patients with lung cancer were higher than those in controls and benign lung lesions. There was a significant difference between the two groups (P<0.05); CYFRA21-1, NSE, and CEA in the lung cancer group. The positive rates were 68.42% (65/95), 36.84% (35/95), and 73.68% (70/95) respectively, and the combined detection positive rate was 95.79% (91/95). Meanwhile, different pathologies were found in the lung cancer group. There was a statistically significant difference in the classification of CYFRA21-1, NSE, and CEA (P<0.05). Conclusion The clinical application of tumor markers such as CYFRA21-1, NSE and CEA in lung cancer patients can not only improve the diagnostic accuracy, but also help determine the prognosis.